1. Others
  2. Others
  3. (Arg)9

(Arg)9 (Synonyms: Nona-L-arginine; Peptide R9)

Cat. No.: HY-P0133
Handling Instructions

(Arg)9 (Nona-L-arginine;Peptide R9) is a cell-penetrating peptide; exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model.

For research use only. We do not sell to patients.

(Arg)9 Chemical Structure

(Arg)9 Chemical Structure

CAS No. : 143413-47-2

Size Stock
100 mg   Get quote  
250 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Other In-stock Forms of (Arg)9:

Other Forms of (Arg)9:

Top Publications Citing Use of Products

1 Publications Citing Use of MCE (Arg)9

  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review

Description

(Arg)9 (Nona-L-arginine;Peptide R9) is a cell-penetrating peptide; exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model.

IC50 & Target

IC50: 0.78 μM (neuroprotection)[1]

In Vitro

Poly-arginine (e.g. (Arg)9) and arginine-rich peptides (e.g. TAT, penetratin), which belong to a class of peptides with cell-penetrating properties are neuroprotective. (Arg)9 provides significant neuroprotection in a dose–response manner following glutamic acid exposure (IC50=0.78 μM). Following kainic acid exposure, (Arg)9 is neuroprotective, but less effective than in the glutamic acid model (IC50=0.81 μM). (Arg)9 also shows neuroprotection following in vitro ischemia (IC50=6 μM)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

(Arg)9) (D-isoform) is neuroprotective in rat stroke models. (Arg)9) is highly neuroprotective, with efficacy increasing with increasing arginine content, has the capacity to reduce glutamic acid-induced neuronal calcium influx and requires heparan sulfate preotoglycan-mediated endocytosis to induce a neuroprotective effect[2]. (Arg)9) (D-isoform) administered intravenously at a dose of 1000 nmol/kg 30 min after permanent middle cerebral artery occlusion (MCAO) reduces infarct volume[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial
Molecular Weight

1423.69

Formula

C₅₄H₁₁₀N₃₆O₁₀

CAS No.
Sequence

Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg

Sequence Shortening

RRRRRRRRR

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References
Cell Assay
[1]

(Arg)9 is prepared as 100× stocks (500 μM) in normal saline and assessed in a concentration range from 0.1 to 15 μM. (Arg)9 is added to culture 96-well plate 15 min prior to glutamic acid or kainic acid exposure. Neuronal viability is quantitatively using the MTS assay[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[2]

Rats: (Arg)9 (D-isoform) is prepared in 100× stocks (500 μM in water and assessed in a concentration range from 0.1 to 20 μM. Rats are fasted overnight and subjected to filament permanent middle cerebral artery occlusion (MCAO). Thirty minutes post-MCAO rats are intravenously treated with (Arg)9 (1 μmol/kg in 600 μL over 5 minutes) or vehicle (normal saline for injection; 600 μL over 5 minutes). Treatments are randomized and all procedures are performed masked to treatment. Twenty-four hours post-MCAO infarct area assessment is performed[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
(Arg)9
Cat. No.:
HY-P0133
Quantity:
MCE Japan Authorized Agent: